Queen Mary University of London
The STORM CHASER study is looking at whether a combination of two investigational antibodies, developed by AstraZeneca, works in the prevention of COVID-19, following exposure to a confirmed infected person. The long-acting drug combination, known as AZD7442, uses monoclonal antibodies which have been created in a laboratory, rather than produced by the body, to help fight infection.
The study is being run in the UK and the US and there are six UK hospital sites currently enrolling. There are now 114 patients taking part, but the study aims to recruit a total of 1,125 people within the next 2-3 weeks.